 M06-806 NCT NCT00409682 was a Phase 3, multi-center, randomized, double-blind DB, efficacy, safety, and pharmacokinetic PK study designed to evaluate the efficacy of 2 dose regimens for the induction and maintenance of clinical remission in pediatric subjects between the ages of 6 and 17 inclusive with moderate to severe Crohns disease CD defined by Pediatric Crohns Disease Activity Index PCDAI 30. Subjects must have either failed conventional therapy for CD or have previously received infliximab and lost responsehad intolerance to infliximab. 